Navigation Links
Imagenetix, Inc. Announces Interview With Bloomberg Radio
Date:8/17/2009

le channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)-Celadrin(R). Please visit, www.celadrin.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

    Contact Imagenetix Investor Relations     William P. Spencer
            (858)385-2797                     Chief Executive Officer
                                              Imagenetix, Inc.
                                              Tel: (858) 674-8455


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Imagenetix, Inc. Reports First Quarter 2010 Results
2. Imagenetix, Inc. Reports Second Quarter and Six Month Results
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
5. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
6. Spectral announces second quarter 2009 results
7. Genoptix Announces Participation at the 2009 Southern California Investor Conference
8. Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona(TM) ) in Mild to Moderate Alzheimers Disease
9. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
10. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
11. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...people would like to be able to charge their cell ...not too often. A recent discovery made by UC San D... supercapacitors that could do just this. , In ...ters , Prabhakar Bandaru, a professor in the UCSD ..., along with graduate student Mark Hoefer, have fo...
(Date:11/19/2009)..., BLAUVELT, N.Y., Nov. 19 Dr. Mate...extract, responds to a press release issued on Nov...rian company for making false and self-serving sta...nces. ,, Dr. Hidvegi stated from his office in...hat research on Avemar does not apply to AveULTRA,...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 ...or in biotechnology for diabetes therapy, and a pr...ices to food, supplement, biotechnology and pharma... Tuesday,s Annual Meeting of Shareholders. ,, A...d (Nasdaq: SPEX ) elected the following members t...
(Date:11/19/2009)..., MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeu...patient in a randomized Phase 2B study of AEG35156...velopment for multiple oncology indications. ,,...se 2 Study of the X-Linked Inhibitor of Apoptosis ...h High-dose Cytarabine and Idarubicin in AML Follo...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
... 13 Hollingsworth & Vose,Company (H&V), a leading...,today introduced its HVision(TM) technology platf...he development and commercialization of,breakthrou...hanced R&D process focused on,creating a new gener...benchmarks in the industry," said Val Hollingswort...
... Equity Research, Inc.,(Scimitar) issues a review ...I), entitled, "Injecting Confidence to the Viprine...ains Do Move". This review is available at our we...ogical Technologies, Inc. (NTII) is a biotechnolog... developing central nervous system,related drug ca...
...Corporation (OTC,Bulletin Board: KDUS.OB) announce...ded September 30, 2007. Revenues were $0 for the ...006. Net income for the third quarter of 2007 was ...he same period in 2006. Basic net income per,share...he same period in,2006. Revenues were $100,000 fo...
Other Biology Technology:H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products 2Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc. 2Cadus Reports Third Quarter 2007 Results 2Cadus Reports Third Quarter 2007 Results 3Cadus Reports Third Quarter 2007 Results 4
(Date:11/22/2009)...tre, a partnership of the University of British Co...ealth Research Institute, have uncovered new infor...e following a stroke, as well as a possible way to...re recently published online in Nature Medicine .... to die even after blood flow has been restored. R...
(Date:11/20/2009)... plasma lipoprotein concentrations determined by n...archers led by Daniel Chasman at Brigham and Women...MA, the Framingham Heart Study in Framingham, and ...Oxford, England performed genetic association anal... European ancestry from the Women,s Genome Health ...
(Date:11/20/2009)...009 The estimated 4.6 million Americans involved ...g respiratory symptoms due to poor air quality in ...dertaken earlier this year by investigators at Tuf...cine. , The studywhich polled more than 80 New E...individuals working in barns complained of coughin...
Breaking Biology News(10 mins):New understanding about mechanism for cell death after stroke leads to possible therapy 2Genetic analysis helps dissect molecular basis of cardiovascular disease 2Barn personnel experience higher-than-average rates of respiratory symptoms 2President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 1President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 2President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 3Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 12734 1Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 12734 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 12734 3Social Activity Keeps Elders Young Agile 49673 1Social Activity Keeps Elders Young Agile 49673 2Social Activity Keeps Elders Young Agile 49673 3
...handful of very special mice, scientists have disc...emical signature implicated in the development of ...box" of opportunity and possibility, study authors...Comprehensive Cancer Center bred a type of mouse t...he mouse first goes through a pre-leukemic stage m...
...s been looking for a "Fontaine de Jouvence" foreve...where to be found, we are making,progress; in worm...,humans had the unexpected effect of prolonging th...e medications slows the rate of aging in,roundworm...ty School of,Medicine in St. Louis. When exposed t...
...d class of drugs that keep the HIV-virus infection...tentially lethal heart rhythm disturbances in some...igation appears in the current edition of The Lan...HIV Program of Hennepin County Medical Center, Min..., and University of Wisconsin, Madison, the Mayo C...
Other Biology News:Genome-wide mouse study yields link to human leukemia 2Genome-wide mouse study yields link to human leukemia 3Research on Worms Yields Clues on Aging 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 3
Diethyl pyrocarbonate from Research Organics, Inc.
Rabbit Anti-JMJD2D Polyclonal Antibody, Unconjugated from Abcam
Permeabilization Solution, 5X from CHEMICON
Cytofix/Cytoperm Kit from BD Biosciences Pharmingen
Biology Products: